ERBB2 and breast carcinoma: On the other hand, although estrogen receptor-negative and HER2-positive have shown evidence of immunogenicity [65], these types of inflammatory breast tumors are rare (1–5% of cases) [68] when compared to triple negative breast tumors, which are unique among breast cancer subtypes in having strong antigen expression [69] and high stromal and tumor-infiltrating lymphocytes, parameters with a strong prognostic and predictive significance to immunotherapy and chemotherapy [62,63,70,71].